Comparative Cost-Effectiveness Of Plerixafor Plus Granulocyte-Colony Stimulating Factor Versus Cyclophosphamide Plus Granulocyte-Colony Stimulating For Autologous Peripheral Blood Stem Cell Mobilization In Patients With Non-Hodgkin's Lymphoma

Christopher J. Campen, EP Armstrong, Jonathan Timothy Christian, S. Hadeed, Andrew M. Yeager

Biology of Blood and Marrow Transplantation · 2010 · 10 citations · 0 references

DOIFull text

Open access

Concepts

Abstract

Chemomobilization of autologous peripheral blood stem cells (PBSCs) is costly and requires substantial resource allocations. This burden has considerable effects on patients (pts), providers and payers. We performed a retrospective study to evaluate the difference in costs and effectiveness of first-line mobilization of autologous PBSCs with cyclophosphamide (CY; 1.5-4 gm/m2)+G-CSF (n=34) versus plerixafor+G-CSF (n=8) in pts with non-Hodgkin's lymphoma (NHL) between 6/2006 and 8/2009.